A detailed history of Barclays PLC transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 139 shares of BOLT stock, worth $70. This represents 0.0% of its overall portfolio holdings.

Number of Shares
139
Previous 139 -0.0%
Holding current value
$70
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 03, 2023

SELL
$1.27 - $1.95 $10 - $15
-8 Reduced 5.44%
139 $0
Q1 2023

May 04, 2023

SELL
$1.29 - $1.66 $1,971 - $2,536
-1,528 Reduced 91.22%
147 $0
Q4 2022

Feb 13, 2023

BUY
$1.26 - $1.51 $1,935 - $2,319
1,536 Added 1105.04%
1,675 $2,000
Q3 2022

Nov 03, 2022

SELL
$1.48 - $2.61 $177 - $313
-120 Reduced 46.33%
139 $0
Q2 2022

Aug 12, 2022

SELL
$1.41 - $2.91 $13,107 - $27,051
-9,296 Reduced 97.29%
259 $0
Q1 2022

May 16, 2022

BUY
$2.74 - $4.82 $26,180 - $46,055
9,555 New
9,555 $26,000

Others Institutions Holding BOLT

About Bolt Biotherapeutics, Inc.


  • Ticker BOLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,641,500
  • Market Cap $19.2M
  • Description
  • Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...
More about BOLT
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.